jRCT2031200299进行中（未招募）不适用
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naive Patients with Mayo Stage IIIb AL Amyloidosis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 3
- 主要终点
- overall survival
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Each patient must meet the following criteria to be enrolled in this study.
- •1.Provide written informed consent and be willing and able to comply with all study procedures
- •2.Adult, 18 years and older
- •3.AL amyloidosis Mayo stage IIIb based on the 2013 European Modification of the 2004 Standard Mayo Clinic Staging in patients with advanced cardiac involvement at the time of Screening
- •4.Measurable hematologic disease at Screening as defined by at least one of the following:
- •a.Involved/Uninvolved Free Light Chain Difference (dFLC) > 4 mg/dL or
- •b.Involved Free Light Chain (iFLC) > 4 mg/dL with abnormal ratio or
- •c.Serum Protein Electrophoresis (SPEP) m-spike > 0.5 g/dL
- •5.Histopathological diagnosis of amyloidosis AND confirmation of AL derived amyloid deposits by at least one of the following:
- •a.Immunohistochemistry or
- •b.Mass spectrometry or
- •c.Characteristic electron microscopy appearance
- •6.Cardiac involvement as defined by:
- •a.Documented clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure AND
- •b.At least one of the following:
- •i. Endomyocardial biopsy demonstrating AL cardiac amyloidosis or
- •ii. Echocardiogram demonstrating a mean left ventricular wall thickness > 12 mm at diastole in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening or
- •iii. Cardiac MRI with gadolinium contrast agent diagnostic or cardiac amyloidosis
- •7.Planned first-line treatment for plasma cell disorder is CyBorD administered as Standard of Care (SoC)
- •8.Adequate bone marrow reserve and hepatic and renal function as demonstrated by:
- •a.Absolute neutrophil count >= 1.0 x 109/L
- •b.Platelet count >= 75 x 109/L
- •c.Hemoglobin >= 9 g/dL
- •d.Total direct bilirubin <= 2 times the upper limit of normal (x ULN) unless due to Gilbert's syndrome.
- •e.Aspartate aminotransferase (AST) <= 3 x ULN
- •f.Alanine aminotransferase (ALT) <= 3 x ULN
- •g.Alkaline phosphatase (ALP) <= 5 x ULN (except for patients with hepatomegaly and isozymes specific to liver, rather than bone)
- •h.Estimated glomerular filtration rate (eGFR) >= 15 mL/min
- •9.Women of childbearing potential (WOCBP) must have a negative pregnancy test during Screening and must agree to use effective physician approved contraception from Screening to 90 days following the last study drug administration
- •10.Men must be surgically sterile or must agree to use effective physician approved contraception from Screening to 90 days following the last study drug administration
排除标准
- •Patients who meet any of the following criteria will not be permitted entry to the study.
- •1.Have any other form of amyloidosis other than AL amyloidosis
- •2.Received prior therapy for AL amyloidosis or multiple myeloma. A maximum exposure of 160 mg dexamethasone (or equivalent corticosteroid) since diagnosis of AL amyloidosis and prior to randomization is allowed.
- •3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma or POEMS syndrome
- •4.Have supine systolic blood pressure < 90 mmHg or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 30 mmHg despite medical management (e.g., midodrine, fludrocortisones) in the absence of volume depletion
- •5.Taking prednisone or its equivalent > 10 mg/day
- •6.Taking doxycycline
- •7.Receiving dialysis
- •8.Planned stem cell transplant during the first 6 months of protocol therapy. Stem cell collection during the protocol therapy is permitted.
- •9.Have had myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias within 6 months prior to screening or percutaneous cardiac intervention with recent stent or coronary artery bypass grafting within 4 months prior to screening
- •10.Left Ventricular Ejection Fraction (LVEF) is < 40% by echocardiogram at Screening
- •11.Have severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area < 1.0 cm2) or severe congenital heart disease
- •12.Have history of sustained ventricular tachycardia or aborted ventricular fibrillation or a history of atrioventricular nodal or sinoatrial nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillator (ICD) is indicated but not placed. (Participants who do have a pacemaker or ICD are allowed in the study.)
- •13.QT corrected by Fridericia (QTcF) is > 550 msec. Participants who have a pacemaker may be included regardless of calculated QTc interval.
- •14.There is evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:
- •a.First degree Atrioventricular (AV)-block
- •b.Second degree AV-block Type 1 (Mobitz Type 1/Wenckebach type)
- •c.Right or left bundle branch block
- •d.Atrial fibrillation with a controlled ventricular rate. (An uncontrolled ventricular rate [i.e., > 110 beats per minute] determined by an average of three beats in lead II or representative beats in lead II is not allowed)
- •15.Have had major surgery within 4 weeks of randomization or is planning major surgery during the study. Patients with surgical procedures conducted under local anesthesia may participate
- •16.There is active malignancy (including lymphoma) with the exception of any of the following:
- •a.Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
- •b.Adequately treated stage I cancer from which the patient is currently in remission and has been in remission for > 2 years
- •c.Low-risk prostate cancer with Gleason score < 7 and prostate-specific antigen < 10 mg/mL
- •d.Other localized and/or low risk malignancies may be permitted with Medical Monitor approval.
- •17.Have received an investigational drug/device in another clinical investigational study within 60 days before Screening
- •Hypersensitivity to the study drug
- •Have received a live vaccine within 4 weeks prior to first dose of CyBorD
- •Women who are breast feeding
- •Have any other medical, social or psychological factors that could affect the patient's safety or ability to consent personally or comply with study procedures.
结局指标
主要结局
overall survival
To determine if CAEL-101 and treatment for PCD improves overall survival in Mayo stage IIIb AL amyloidosis patients who are treatment naive compared to treatment for PCD alone
safety and tolerability
To evaluate the safety and tolerability of CAEL-101 in combination with treatment for PCD
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisEUCTR2005-001187-31-CZTAP Pharmaceutical Products Inc.1,950
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisEUCTR2005-001189-15-GBTAP Pharmaceutical Products Inc.360
进行中（未招募）
不适用
A Study to Test the Effect and Safety of Brodalumab Compared WithPlacebo and Ustekinumab and the Results of Changing Strength orFrequency of Brodalumab in People with Moderate to Severe PlaquePsoriasis: AMAGINE-3Moderate to severe plaque psoriasisMedDRA version: 15.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-000667-24-ITAMGEN INC.1,800
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive EsophagitisErosive esophagitisEUCTR2005-001187-31-HUTAP Pharmaceutical Products Inc.1,950
招募中
1 期
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia SyndromeFamilial Chylomicronemia SyndromeMedDRA version: 24.1Level: LLTClassification code 10085051Term: Familial chylomicronemia syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-003680-10-ATArrowhead Pharmaceuticals, Inc.72